MANUEL CHAVARRIA: Open Payments
NPI 1578614921 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$452 in 23 payments from 9 companies in 2025. Trend: 2023 $338 · 2024 $454 · 2025 $452
Food & beverage: $452
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 8 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $91 |
| Novo Nordisk Inc | 4 | $90 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| PFIZER INC. | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| SHIELD THERAPEUTICS INC | 1 | $19 |
| Organon LLC | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: JARDIANCE, MOUNJARO, Ozempic, PAXLOVID, Dexcom G6 Transmitter, FARXIGA, ACCRUFER, NEXPLANON.
Industry payments across TX — which companies pay providers there.
